有下尿路症状的良性前列腺增生患者前列腺特异性抗原检测的临床意义

Clinical Significance of Prostatic-specific Antigen Levels in Patients with Benign Prostatic Hyperplasia Complicated by Low Urinary Tract Syndrome

目的:探讨前列腺特异性抗原(PSA)测定在有下尿路症状的良性前列腺增生(BPH)患者的临床意义。方法:比较520例有症状和196例无症状的BPH患者的总PSA(tPSA),游离PSA(fPSA)和fPSA/tPSA等指标,并进行统计学分析。结果:有症状组和无症状组的tPSA值分别为(5.13±2.49)、(1.73±1.26)μg/L,差异有极显著性(P<0.01);fPSA分别为(1.57±0.80)、(0.54±0.38)μg/L,差异有极显著性(P<0.01);fPSA/tPSA分别为0.31±0.09和0.30±0.11,差异无显著性(P>0.05)。结论:有下尿路症状BPH患者的tPSA、fPSA明显高于无症状,但fPSA/tPSA比值在BPH患者中稳定。

Objective： To evaluate the clinical significance of prostatic-specific antigen （PSA） levels in patients with benign prostatic hyperplasia （BPH） complicated by low urinary tract syndrome（LUTS）. Methods. The levels of tPSA, tTSA and tTSA/tPSA ratio were detected and compared in 520 cases of BPH with LUTS and 196 cases without LUTS. Results ： The mean levels of tPSA in the cases of BPH with LUTS and without LUTS were （ 5.13±2.49 ）μg/L and （ 1.73 ±1.26）μg/L respectively （ P 〈 0.01 ）. The mean levels fPSA were （ 1.57 ±0.80） μg/L and （0.54±0.38 ）μg/L respectively（ P 〈 0.01 ）. The mean ratios of fPSA/tPSA were （0.31±0.09 ） and （ 0.30±0.11 ） respectively （ P 〉 0.05 ）. Conclusion ： The levels of tPSA, fPSA are significantly higher in the cases of BPH with LUTS than those in the cases without LUTS, but the ratio of fPSA/tPSA is stable in BPH.